Impact of multigene assays in early stage breast cancer

Oncologist

Volumn 16, Issue 11, 2011, Pages 1482-1483

  Lo, Shelly S ^a   Albain, Kathy S ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; GENETIC ALGORITHM; GENETIC ANALYSIS; HORMONE ACTION; MITOSIS RATE; MONOTHERAPY; MULTIGENE FAMILY; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUALITY CONTROL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT PLANNING; TUMOR GROWTH; VALIDATION PROCESS;

BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN;

EID: 82355164826     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0325     Document Type: Article

References (20)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360: 790-800.
2. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene as-says. Breast 2009;18(suppl 3):S141-S145.
3. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
4. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a ran-domised trial. Lancet Oncol 2010;11:55-65.
5. Joh JE, Esposito NN, Kiluk JV et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. The Oncologist 2011;16:1520-1526.
6. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-1676.
7. Albanell J, Gonzalez A, Borrego MR et al. Pro-spective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER) node-negative breast cancer. Ann Oncol 2011 Jun 6 [Epub ahead of print].
8. Hornberger JC, Chjien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice [abstract P201]. Pre-sented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
9. Holt ADH, Bertelli G, Pudney D et al. Results from a prospective clinical study on the impact of oncotype DX on adjuvant treatment decision and risk classification by Nottingham prognostic index (NPI) and recurrence score (RS) [abstract P196]. Presented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
10. Blohmer JU, Ataseven B, Kuhn T et al. German multicentre decision impact study of oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER) node negative (N0) and node positive (N) early breast cancer [abstract P206]. Presented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
11. Cuzick J, Dowsett M, Wale C et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score-results from transATAC. Cancer Res 2009;69(24 suppl):74.
12. Flanagan MB, Dabbs DJ, Brufsky AM et al. Histopathologic variables predict oncotype DX recurrence score. Mod Pathol 2008;21:1255-1261.
13. Geradts J, Bean SM, Bentley RC et al. The on-cotype DX recurrence score is Correlated with a composite index including routinely reported patho-biologic features. Cancer Invest 2010;28:969-977.
14. Goldhirsch A, Wood WC, Coates AS et al. Strat egies for subtypes- dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 201. Ann Oncol 2011;22:1736-1747.
15. Hassan S, Mittmann N. A cost benefit analysis of the 21-gene breast cancer assay within a Canadian health care system [abstract 6111]. Presented at the 2011 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 4-8, 2011.
16. Madaras B, Pozsa P, Gerencser Z et al. Evaluation of the cost-effectiveness of oncotype DX multigene assay in Hungary [abstract P215B]. Presented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
17. Liaropoulos L, Galanis P, Kaitelidou D et al. Gross financial evaluation of the application of the 21-gene assay oncotype DX for adjuvant chemo-therapy decision-making in estrogen receptor-positive node negative breast cancer in Greece [abstract P202]. Presented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
18. De Lima Lopes G, Chien R, Hornberger JC. Cost-benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore [abstract P215A]. Presented at the 2011 St. Gallen Oncology Conference, St. Gallen, Switzerland, March 16-19, 2011.
19. Lyman GH, Cosler LE, Kuderer NM et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 2007;109:1011-1018.
20. Tang G, Shak S, Paik S et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127: 133-142.